Gate Bioscience develops small-molecule medicines that block disease-causing proteins from leaving cells, aiming to treat inflammatory and neurological diseases with oral drugs.

Products & media

Molecular Gate Discovery Platform

Partnered drug-discovery platform for small molecules that selectively block disease-causing proteins from secretion, supporting Gate’s therapeutic-development collaboration with Lilly.

Cosigns

Vineeta AgarwalaGeneral Partner at Andreessen Horowitz
“With its powerful discovery engine, cutting-edge technologies, and leading team, Gate is poised to realize the potential of this new modality.”
Source
Jordi Mata-FinkCo-founder and CEO of Gate Bioscience
“Our platform has matured into a true drug discovery engine, allowing us to create selective Molecular Gates repeatedly and efficiently”
Source
Pat SharpCo-founder and scientific advisor at Gate Bioscience
“This Series B validates our differentiated approach: turning the cell’s single protein exit channel into a precision therapeutic target.”
Source

Team

3 people across company lists

Current Affiliates

3 people

List
Raman Talwar2021-05
Jordi Mata-Fink2021-07
Pat Sharp2026-07

Jobs

See all jobs for Gate Bioscience here.

Funding

All fundraising announcements are based on public sources. Please contact Cosign if you believe there are any discrepancies, or claim the profile to edit.

Leads

Participating Firms

Angels

Lilly strategic equity investment

Undisclosed amount

View post